$IBIO News

iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial

iBio Q3 EPS $(0.07) Misses $(0.06) Estimate

iBio Gets Australian Regulatory Clearance For First-In-Human Phase 1 Trial Of IBIO-600, A Long-Acting Anti-Myostatin Antibody Targeting Muscle Loss In Obesity

iBio Gets Australian Regulatory Clearance For First-In-Human Phase 1 Trial Of IBIO-600, A Long-Acting Anti-Myostatin Antibody Targeting Muscle Loss In Obesity

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026

iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals

Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7

iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program

iBio Files Preliminary Prospectus To Issue Up To $200M In Securities

iBio to Participate in Upcoming Investor Conferences

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

IBIO Inc (NASDAQ:IBIO) Secures $26 Million Lifeline Amid Quarterly Earnings Miss

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Earnings Review: Q2 Summary

iBio Q2 EPS $(0.09) Misses $(0.07) Estimate

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

iBio Files Prospectus For Resale Of 11,061,738 Shares Of Common Stock By Selling Stockholders

iBio shares are trading higher after the company announced a $26 million private placement.

iBio Announces $26 Million Private Placement